The identification of the brain-specific aromatase promoter and the activity of local estrogen through ERα and its downstream regulator, seladin-1, propose these enzymes to be new targets in drug design for the treatment of neurodegenerative diseases, such as AD, stroke, and epilepsy. The gene discussed is CYP19A1; the disease is neurodegenerative disease.